Get the Stockscreener App
1.635
4.81%
0.075
Humacyte Inc stock is traded at $1.635, with a volume of 851.08K.
It is up +4.81% in the last 24 hours and up +11.22% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.56
Open:
$1.6
24h Volume:
851.08K
Relative Volume:
0.17
Market Cap:
$259.70M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.528
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-34.07%
1M Performance:
+11.22%
6M Performance:
+6.86%
1Y Performance:
-71.47%
1-Day Range:
$1.5914
$1.645
1-Week Range:
$1.55
$1.969
52-Week Range:
$1.15
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.635 | 292.14M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Understanding Humacyte Inc. Equity Warrant’s price movementJuly 2025 Volume & Comprehensive Market Scan Reports - newser.com
Is Humacyte Inc. stock trading near support levelsWeekly Trend Report & AI Forecasted Stock Moves - newser.com
Live market analysis of Humacyte Inc. Equity WarrantJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - newser.com
Using fundamentals and technicals on Humacyte Inc. Equity WarrantEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com
Relative strength of Humacyte Inc. in sector analysisMarket Movers & Long-Term Growth Plans - newser.com
Will Humacyte Inc. stock gain from government policiesJobs Report & Verified Short-Term Plans - newser.com
Can a trend reversal in Humacyte Inc. Equity Warrant lead to recoveryTrade Entry Summary & Entry Point Strategy Guides - newser.com
Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise - Yahoo
Humacyte shares sink as it announces pricing of $60M direct offering - MSN
Advanced analytics toolkit walkthrough for Humacyte Inc.Take Profit & Long-Term Capital Growth Strategies - newser.com
Top chart patterns to watch in Humacyte Inc.Earnings Overview Summary & AI Powered Market Entry Ideas - newser.com
Building trade automation scripts for Humacyte Inc.July 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
Real time social sentiment graph for Humacyte Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-10-10 04:58:04 - newser.com
Is Humacyte Inc. stock poised for growthWeekly Trade Report & Safe Capital Growth Plans - newser.com
Humacyte Announces $60M Stock and Warrants Offering - MSN
Published on: 2025-10-09 06:28:01 - newser.com
Is Humacyte Inc. Equity Warrant stock positioned for digital transformation2025 Retail Activity & Real-Time Volume Triggers - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc.Common Stock (NQ: - FinancialContent
Combat Trauma Study Results Might Change The Case For Investing In Humacyte (HUMA) - simplywall.st
What analysts say about Humacyte Inc stockRisk Mitigation Techniques & Fast Growing Investment Plans - earlytimes.in
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors - Yahoo Finance
Investors Buy High Volume of Call Options on Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte: Shares Tank On Fundraising NewsWhat You Need To Know (NASDAQ:HUMA) - Seeking Alpha
Humacyte Gains 43%, Insider Trades Reap Benefit - Yahoo
Humacyte (HUMA) Valuation in Focus After Encouraging Ukraine Trauma Results and New Patent Milestone - simplywall.st
Humacyte shares plunge after announcing $60 million registered direct offering - MSN
Humacyte Prices $60 Million Oversubscribed Registered Direct Offering; Shares Tumble - MarketScreener
Humacyte prices 28.4M shares at $2.11 in registered direct offering - TipRanks
Humacyte secures $60 million in registered direct offering - Investing.com
Humacyte stock tumbles after $60 million registered direct offering - Investing.com
Humacyte announces pricing of $60.0 million oversubscribed registered direct offering - MarketScreener
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering - MarketScreener
Is Humacyte Inc a good long term investmentMean Reversion Trades & Breakthrough Stock Performance - earlytimes.in
Humacyte rises after positive data from humanitarian study of Symvess - MSN
HUMA: D. Boral Capital Maintains 'Buy' Rating with $25 Price Tar - GuruFocus
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte reports positive long-term results for vascular trauma device - Investing.com India
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - The Manila Times
Humacyte, Inc. Reports Zero Infections and High Patency Rates for Symvess in Military Medicine Journal Publication on Wartime Vascular Trauma Treatment - Quiver Quantitative
87.1% patency in 17 patients — Humacyte's Symvess shows zero infections, amputations or deaths - Stock Titan
How to monitor Humacyte Inc. with trend dashboardsEarnings Recap Summary & AI Enhanced Trading Alerts - newser.com
Why Humacyte Inc. stock remains undervaluedTrade Volume Summary & High Conviction Buy Zone Alerts - newser.com
How to integrate Humacyte Inc. Equity Warrant into portfolio analysis toolsPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Developing predictive dashboards with Humacyte Inc. dataJuly 2025 Update & High Yield Stock Recommendations - newser.com
Is Humacyte Inc. Equity Warrant a candidate for recovery playTrade Exit Summary & Long Hold Capital Preservation Tips - newser.com
Using economic indicators to assess Humacyte Inc. potentialWeekly Risk Report & Stock Market Timing Techniques - newser.com
Is Humacyte Inc. stock entering bullish territory2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Humacyte Inc Stock (HUMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dougan Brady W | Director |
Aug 18 '25 |
Sale |
1.83 |
549,360 |
1,005,329 |
1,691,685 |
| Dougan Brady W | Director |
Aug 20 '25 |
Sale |
1.58 |
591,685 |
934,862 |
0 |
| Niklason Laura E | President, CEO and Director |
Aug 19 '25 |
Sale |
1.63 |
1,100,000 |
1,793,000 |
591,685 |
| Niklason Laura E | President, CEO and Director |
Aug 18 '25 |
Sale |
1.83 |
549,360 |
1,005,329 |
1,691,685 |
| Niklason Laura E | President, CEO and Director |
Aug 20 '25 |
Sale |
1.58 |
591,685 |
934,862 |
0 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):